• Integrated Phase I/lll study for proposed biosimilar denosumab to confirm matching efficacy, safety and immunogenicity with reference medicine[1] 
• Osteoporosis accounts for 8.9m bone fractures annually, including debilitating hip fractures — number set to increase substantially over next two decades[2]
• Sandoz has eight marketed biosimilar medicines globally and 10+ molecules in the pipeline including proposed biosimilar denosumab

Holzkirchen, July 22, 2019 – Sandoz, a Novartis division and a global leader in …